• 1. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Introduction to (S)-4-amino-1-methylpyrrolidin-2-one (CAS No. 770706-26-8)

(S)-4-amino-1-methylpyrrolidin-2-one is a significant compound in the field of pharmaceutical chemistry, characterized by its unique structural and functional properties. This compound, identified by the CAS number 770706-26-8, has garnered considerable attention due to its potential applications in drug development and medicinal chemistry. The enantiomeric purity and stereochemical configuration of this molecule play a crucial role in determining its biological activity, making it a subject of extensive research and innovation.

The chemical structure of (S)-4-amino-1-methylpyrrolidin-2-one consists of a pyrrolidinone core substituted with an amino group at the fourth position and a methyl group at the first position. This specific arrangement imparts unique reactivity and binding properties, which are highly valuable in the design of novel therapeutic agents. The stereochemistry of the molecule, particularly the (S) configuration, is critical for its interaction with biological targets, influencing both efficacy and selectivity.

In recent years, there has been a surge in research focused on developing chiral auxiliaries and ligands for asymmetric synthesis. (S)-4-amino-1-methylpyrrolidin-2-one has emerged as a promising candidate in this area, owing to its ability to facilitate enantioselective transformations. Studies have demonstrated its utility in catalytic processes that yield high enantiomeric excess products, which are essential for pharmaceutical applications. The compound’s role in asymmetric hydrogenation and oxidation reactions has been particularly noteworthy, contributing to advancements in synthetic methodologies.

The pharmaceutical industry has shown immense interest in (S)-4-amino-1-methylpyrrolidin-2-one due to its potential as a building block for more complex drug molecules. Its structural features make it a versatile intermediate in the synthesis of bioactive compounds, including those targeting neurological disorders, inflammatory diseases, and infectious pathogens. Researchers have explored its incorporation into peptidomimetics and small-molecule inhibitors, leveraging its scaffold to enhance drug-like properties such as solubility, bioavailability, and metabolic stability.

One of the most compelling aspects of (S)-4-amino-1-methylpyrrolidin-2-one is its role in medicinal chemistry innovation. The compound’s ability to serve as a precursor for diverse pharmacophores has led to the discovery of several lead compounds with therapeutic potential. For instance, derivatives of this molecule have been investigated for their antimicrobial and anti-inflammatory effects. The structural flexibility offered by the pyrrolidinone ring allows for modifications that can fine-tune biological activity, making it an invaluable asset in drug discovery pipelines.

The synthetic pathways for producing (S)-4-amino-1-methylpyrrolidin-2-one have also been refined through recent advancements in organic chemistry. Techniques such as chiral resolution and enzymatic catalysis have enabled the efficient preparation of enantiomerically pure samples, which are indispensable for preclinical and clinical studies. These methodologies not only enhance production efficiency but also reduce costs associated with purification and isolation processes.

In conclusion, (S)-4-amino-1-methylpyrrolidin-2-one (CAS No. 770706-26-8) represents a cornerstone in modern pharmaceutical research. Its unique structural attributes and stereochemical properties make it an indispensable tool for developing innovative therapeutic agents. As research continues to uncover new applications and synthetic strategies, this compound is poised to play an even more significant role in advancing drug discovery and development across multiple therapeutic areas.

• 1128-77-4(3,9-Diazabicyclo[4.2.1]nonan-4-one,3,9-dimethyl-)
• 1255718-06-9(4-amino-1-ethyl-2-pyrrolidinone hydrochloride)
• 1255717-37-3(4-Amino-1-propylpyrrolidin-2-one Hydrochloride)
• 1083245-99-1(4-Amino-1-propylpyrrolidin-2-one)
• 143228-30-2(2-Pyrrolidinone, 4-(dimethylamino)-1-methyl-)
• 933744-16-2(4-Amino-1-methylpyrrolidin-2-one)
• 1228838-07-0(4-Amino-1-methylpyrrolidin-2-one hydrochloride)
• 1330170-43-8(rac-(1R,6S)-3-methyl-3,9-diazabicyclo[4.2.1]nonan-4-one)
• 936940-33-9(4-amino-1-(propan-2-yl)pyrrolidin-2-one)
• 1240527-57-4(4-amino-1-(propan-2-yl)pyrrolidin-2-one hydrochloride)